Mike Deridder Email & Phone Number

Glenside, PA, US

Glenside, PA, US

• Interim head of commercial for clinical-stage biotech, responsible for early commercial strategy across portfolio, preliminary go-to-market plan for lead program, and operational roadmap to integrate commercial.
• BD support for preclinical biotech seeking collaborations for their novel gene-editing platform
• Strategic advisor to entrepreneurs exploring business opportunities in the cell therapy space

Boston, Massachusetts, US

• Lead business development strategy and operations, including search and evaluation, oversight of transactional activities, and alliance management
• Responsible for commercial strategy and positioning for pipeline programs, new target prioritization, target product profiles, and competitive positioning
• Oversee corporate communications including corporate presentations, investor relations, and media

Brentford, Middlesex, GB

• Key role in growing GSK Oncology from 3 commercial FTEs post-Novartis transaction to >1000
• Lead commercial and strategic diligence on numerous oncology opportunities spanning cell therapy and Immuno-Oncology, including the $5B acquisition of Tesaro in 2019
• Built cell therapy commercial organization, establishing a global team of 9 FTE and driving the establishment of cell therapy Medical Affairs and regional commercial teams

Brentford, Middlesex, GB

• Responsible for commercial strategy for portfolio of T-cell based oncology therapies, including CAR-T, TCR, and NK cell approaches; partner with R&D Head to design and implement GSK overall cell therapy strategy
• Commercial lead for NY-ESO TCR therapy; led commercial assessment of program and successfully presented case for early execution of GSK option to senior leaders
• Commercial point for search and evaluation of external partnering opportunities with the objective to acquire add-on technologies and complementary cell therapy assets

Brentford, Middlesex, GB

• Commercial lead on ADD and NS Leadership Teams and individual project teams - Lead commercial aspects of strategy and decision making for 20+ clinical programs to Phase II/III - Led governance review of linerixibat.
• Leader of numerous additional initiatives including the development of partnering strategies for ADD assets outside of GSK’s core areas of focus and the development of recommendations to prioritize effort and refine.

Brentford, Middlesex, GB

Brentford, Middlesex, GB

• 1 year initiative to design a process and execute strategies to optimize the commercial value proposition of non-core assets by guiding internal investment and potential partnering decisions
• Assessed the commercial landscape and identified key success factors across multiple therapeutic areas
• Designed and conducted internal capabilities assessment. Leveraged assessments to make organizational recommendations for assets outside of core areas of expertise
• Assembled and led Pioneer Strategy Teams to conduct detailed review of strategic options and recommend optimization strategies for various assets

Brentford, Middlesex, GB

• Responsibility for global strategic and commercial input to various R&D units (including Ophthalmology and Rare Disease) to inform therapeutic area strategy, disease area strategy, and asset value proposition development
• Designed and executed complex multinational research studies across key stakeholder groups to refine disease focus, establish target profile characteristics, define asset strategy, and enable strategic decisions for.
• Evaluated and developed positioning strategy for new areas including stem cells, gene therapy and ocular-related rare diseases
• Partnered with R&D and Business Development to evaluate early platform technologies (e.g., stabilized peptides, microbiome screening) and asset opportunities, resulted in execution of 3 platform agreements currently.
• Core member of team responsible for development and roll-out of novel Early Commercial Process to establish consistency in methodology and excellence in execution across the organization

Boston, MA, US

• Completed over 60 engagements in corporate, commercial and product strategy, company and product valuation, and transaction support, across all stages of product life cycle
• Extensive experience conducting primary and secondary market research, as well as the development of revenue forecasts and valuations, in numerous diseases and across the spectrum of product lifecycle
• Responsible for management and execution of numerous parallel projects, consisting of 3-7 direct reports per engagement
• Presented recommendations to various audiences including Boards of Directors, C-level executives and leaders of Commercial, Strategy, and R&D functions
• Recipient of Quarterly Recognition Award for outstanding performance
• Repeatedly promoted ahead of standard schedule, reducing standard timeline to Engagement Manager by ~6 months

Phd, Bioengineering

Bse, Biomedical Engineering

Education record